CA2433351A1 - Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor - Google Patents

Info

Publication number

CA2433351A1

CA2433351A1 CA002433351A CA2433351A CA2433351A1 CA 2433351 A1 CA2433351 A1 CA 2433351A1 CA 002433351 A CA002433351 A CA 002433351A CA 2433351 A CA2433351 A CA 2433351A CA 2433351 A1 CA2433351 A1 CA 2433351A1

Authority

CA

Canada

Prior art keywords

indol

ester

methylpiperidin

acid

benzenesulfonic acid

Prior art date

2001-01-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 108091005435 5-HT6 receptors Proteins 0.000 title abstract description 34
• 239000005557 antagonist Substances 0.000 title abstract description 11
• UXIVTIPEQSXFBC-UHFFFAOYSA-N 1h-indol-5-yl benzenesulfonate Chemical class C=1C=C2NC=CC2=CC=1OS(=O)(=O)C1=CC=CC=C1 UXIVTIPEQSXFBC-UHFFFAOYSA-N 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims abstract description 222
• 238000000034 method Methods 0.000 claims description 104
• 238000002360 preparation method Methods 0.000 claims description 71
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
• 229910052739 hydrogen Inorganic materials 0.000 claims description 28
• 239000001257 hydrogen Substances 0.000 claims description 27
• XIMWTVNLJKSGBH-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2OS(=O)(=O)C1=CC=CC=C1 XIMWTVNLJKSGBH-UHFFFAOYSA-N 0.000 claims description 25
• -1 benzylsulfonyl Chemical group 0.000 claims description 25
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 20
• 150000003839 salts Chemical class 0.000 claims description 19
• 208000024827 Alzheimer disease Diseases 0.000 claims description 16
• 239000003814 drug Substances 0.000 claims description 15
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
• 239000002253 acid Substances 0.000 claims description 13
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 13
• 229940092714 benzenesulfonic acid Drugs 0.000 claims description 13
• 208000010877 cognitive disease Diseases 0.000 claims description 13
• 125000005843 halogen group Chemical group 0.000 claims description 11
• 239000008194 pharmaceutical composition Substances 0.000 claims description 10
• JZUAGNKBVRSAJD-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 2,6-difluorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2OS(=O)(=O)C1=C(F)C=CC=C1F JZUAGNKBVRSAJD-UHFFFAOYSA-N 0.000 claims description 8
• 150000002148 esters Chemical class 0.000 claims description 8
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
• 201000000980 schizophrenia Diseases 0.000 claims description 8
• 239000003085 diluting agent Substances 0.000 claims description 7
• 125000001153 fluoro group Chemical group F* 0.000 claims description 7
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 5
• TUHDCYAJAMCYOE-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 4-aminobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2OS(=O)(=O)C1=CC=C(N)C=C1 TUHDCYAJAMCYOE-UHFFFAOYSA-N 0.000 claims description 5
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
• KFADWJUCODLDMZ-UHFFFAOYSA-N [1-(benzenesulfonyl)-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CN(S(=O)(=O)C=3C=CC=CC=3)C1=CC=C2OS(=O)(=O)C1=CC=CC=C1 KFADWJUCODLDMZ-UHFFFAOYSA-N 0.000 claims description 4
• SCEHARXOKRVDBE-UHFFFAOYSA-N [3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-1h-indol-5-yl] benzenesulfonate Chemical compound C1N(C)CCC(C=2C3=CC(OS(=O)(=O)C=4C=CC=CC=4)=CC=C3NC=2)=C1 SCEHARXOKRVDBE-UHFFFAOYSA-N 0.000 claims description 4
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
• ZHNJOVZLRYKCHP-UHFFFAOYSA-N [1-(2,6-difluorophenyl)sulfonyl-3-(1-methylpiperidin-4-yl)indol-5-yl] 2,6-difluorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CN(S(=O)(=O)C=3C(=CC=CC=3F)F)C1=CC=C2OS(=O)(=O)C1=C(F)C=CC=C1F ZHNJOVZLRYKCHP-UHFFFAOYSA-N 0.000 claims description 3
• SSURHDVTVNUXPU-UHFFFAOYSA-N [1-[(4-fluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CC1=CC=C(F)C=C1 SSURHDVTVNUXPU-UHFFFAOYSA-N 0.000 claims description 3
• QERFJVVHXQRMMQ-UHFFFAOYSA-N [1-butyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate Chemical compound C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(CCCC)C=C1C1CCN(C)CC1 QERFJVVHXQRMMQ-UHFFFAOYSA-N 0.000 claims description 3
• VGEUFDHJGPEZTP-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 4-nitrobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 VGEUFDHJGPEZTP-UHFFFAOYSA-N 0.000 claims description 3
• 230000008485 antagonism Effects 0.000 claims description 3
• 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 3
• 125000001424 substituent group Chemical group 0.000 claims description 3
• 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 2
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
• GFJSINCJLPAEBP-UHFFFAOYSA-N [1,7-dimethyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CN(C)C1=C(C)C=C2OS(=O)(=O)C1=CC=CC=C1 GFJSINCJLPAEBP-UHFFFAOYSA-N 0.000 claims description 2
• GPVHAPQRXUVNLQ-UHFFFAOYSA-N [1-benzyl-7-methyl-3-(1-methylpiperidin-4-yl)indol-5-yl] 2,6-difluorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C(=CC=CC=2F)F)=CC(C)=C11)=CN1CC1=CC=CC=C1 GPVHAPQRXUVNLQ-UHFFFAOYSA-N 0.000 claims description 2
• ROSXPNMCBNLKBE-UHFFFAOYSA-N [2-methyl-3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 2,6-difluorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=C(C)NC1=CC=C2OS(=O)(=O)C1=C(F)C=CC=C1F ROSXPNMCBNLKBE-UHFFFAOYSA-N 0.000 claims description 2
• GXYCNBXUKZWYBI-UHFFFAOYSA-N [2-methyl-3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=C(C)NC1=CC=C2OS(=O)(=O)C1=CC=CC=C1 GXYCNBXUKZWYBI-UHFFFAOYSA-N 0.000 claims description 2
• HYQBWCHMKUFJTK-UHFFFAOYSA-N [3-(1-methyl-2h-pyridin-4-yl)-1-propylindol-5-yl] benzenesulfonate Chemical compound C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(CCC)C=C1C1=CCN(C)C=C1 HYQBWCHMKUFJTK-UHFFFAOYSA-N 0.000 claims description 2
• JGNHMHJWQIAPBN-UHFFFAOYSA-N [3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-1h-indol-5-yl] 2,6-difluorobenzenesulfonate Chemical compound C1N(C)CCC(C=2C3=CC(OS(=O)(=O)C=4C(=CC=CC=4F)F)=CC=C3NC=2)=C1 JGNHMHJWQIAPBN-UHFFFAOYSA-N 0.000 claims description 2
• WZEIFCRCNCUNTB-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CN(CC(F)(F)F)C1=CC=C2OS(=O)(=O)C1=CC=CC=C1 WZEIFCRCNCUNTB-UHFFFAOYSA-N 0.000 claims description 2
• WIOSJFRMWVIGMD-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 2,4-difluorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2OS(=O)(=O)C1=CC=C(F)C=C1F WIOSJFRMWVIGMD-UHFFFAOYSA-N 0.000 claims description 2
• OTXXWTLWJFSVHO-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 2-fluorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2OS(=O)(=O)C1=CC=CC=C1F OTXXWTLWJFSVHO-UHFFFAOYSA-N 0.000 claims description 2
• NFUJHHPNILEOEJ-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 4-(methanesulfonamido)benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2OS(=O)(=O)C1=CC=C(NS(C)(=O)=O)C=C1 NFUJHHPNILEOEJ-UHFFFAOYSA-N 0.000 claims description 2
• AXZVGTHTHLKSDL-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 4-chlorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2OS(=O)(=O)C1=CC=C(Cl)C=C1 AXZVGTHTHLKSDL-UHFFFAOYSA-N 0.000 claims description 2
• CFRATGPOLALVIY-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 4-fluorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2OS(=O)(=O)C1=CC=C(F)C=C1 CFRATGPOLALVIY-UHFFFAOYSA-N 0.000 claims description 2
• NKDSXYHZUNGVID-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 4-iodobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2OS(=O)(=O)C1=CC=C(I)C=C1 NKDSXYHZUNGVID-UHFFFAOYSA-N 0.000 claims description 2
• BPBIMNSEWAEAHO-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 4-methoxybenzenesulfonate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)OC1=CC=C(NC=C2C3CCN(C)CC3)C2=C1 BPBIMNSEWAEAHO-UHFFFAOYSA-N 0.000 claims description 2
• SQDXGSNEGWIKNR-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 4-methylbenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2OS(=O)(=O)C1=CC=C(C)C=C1 SQDXGSNEGWIKNR-UHFFFAOYSA-N 0.000 claims description 2
• BAMDDAOOKHBFHP-UHFFFAOYSA-N [6-fluoro-3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 2,6-difluorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC(F)=C2OS(=O)(=O)C1=C(F)C=CC=C1F BAMDDAOOKHBFHP-UHFFFAOYSA-N 0.000 claims description 2
• IBXFIXQLFFFHGD-UHFFFAOYSA-N [7-methyl-3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 2,6-dichlorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=C(C)C=C2OS(=O)(=O)C1=C(Cl)C=CC=C1Cl IBXFIXQLFFFHGD-UHFFFAOYSA-N 0.000 claims description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
• 229920002554 vinyl polymer Chemical group 0.000 claims description 2
• JTBDAUNIHPKJQV-UHFFFAOYSA-N [1-benzyl-3-(1-methylpiperidin-4-yl)indol-5-yl] 2,6-difluorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C(=CC=CC=2F)F)=CC=C11)=CN1CC1=CC=CC=C1 JTBDAUNIHPKJQV-UHFFFAOYSA-N 0.000 claims 2
• 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 1
• YODIPMROGSPCJQ-UHFFFAOYSA-N C1=C(C2CCN(C)CC2)C2=CC(OS(=O)(=O)C=3C(=CC=CC=3F)F)=CC(C)=C2N1C(C)C1=CC=CC=C1 Chemical compound C1=C(C2CCN(C)CC2)C2=CC(OS(=O)(=O)C=3C(=CC=CC=3F)F)=CC(C)=C2N1C(C)C1=CC=CC=C1 YODIPMROGSPCJQ-UHFFFAOYSA-N 0.000 claims 1
• YOPYLHIKNWDPGJ-UHFFFAOYSA-N C1=C(C2CCN(C)CC2)C2=CC(OS(=O)(=O)C=3C(=CC=CC=3F)F)=CC=C2N1C(C)C1=CC=CC=C1 Chemical compound C1=C(C2CCN(C)CC2)C2=CC(OS(=O)(=O)C=3C(=CC=CC=3F)F)=CC=C2N1C(C)C1=CC=CC=C1 YOPYLHIKNWDPGJ-UHFFFAOYSA-N 0.000 claims 1
• VPMPOGSTMUSVRT-UHFFFAOYSA-N [1,7-dimethyl-3-(1-methylpiperidin-4-yl)indol-5-yl] 2,6-difluorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CN(C)C1=C(C)C=C2OS(=O)(=O)C1=C(F)C=CC=C1F VPMPOGSTMUSVRT-UHFFFAOYSA-N 0.000 claims 1
• YSHATEOKSXWNON-UHFFFAOYSA-N [1-(cyclohexylmethyl)-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CC1CCCCC1 YSHATEOKSXWNON-UHFFFAOYSA-N 0.000 claims 1
• AKXUEKLFNOGZAB-UHFFFAOYSA-N [1-[(2,4-difluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CC1=CC=C(F)C=C1F AKXUEKLFNOGZAB-UHFFFAOYSA-N 0.000 claims 1
• RCSARYZHFBLLNG-UHFFFAOYSA-N [1-[(2-fluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CC1=CC=CC=C1F RCSARYZHFBLLNG-UHFFFAOYSA-N 0.000 claims 1
• AIMQSRJVQBQZGT-UHFFFAOYSA-N [1-[(3-fluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CC1=CC=CC(F)=C1 AIMQSRJVQBQZGT-UHFFFAOYSA-N 0.000 claims 1
• AYNBKSWTHRGLAY-UHFFFAOYSA-N [1-[(4-fluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)indol-5-yl] 2,6-difluorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C(=CC=CC=2F)F)=CC=C11)=CN1CC1=CC=C(F)C=C1 AYNBKSWTHRGLAY-UHFFFAOYSA-N 0.000 claims 1
• IHQUYRBHNOPXLO-UHFFFAOYSA-N [1-benzyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CC1=CC=CC=C1 IHQUYRBHNOPXLO-UHFFFAOYSA-N 0.000 claims 1
• XQLNCWWWXOZCRT-UHFFFAOYSA-N [1-benzylsulfonyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CN(S(=O)(=O)CC=3C=CC=CC=3)C1=CC=C2OS(=O)(=O)C1=CC=CC=C1 XQLNCWWWXOZCRT-UHFFFAOYSA-N 0.000 claims 1
• DWQOVEHUJOVFIE-UHFFFAOYSA-N [1-cyclohexyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1C1CCCCC1 DWQOVEHUJOVFIE-UHFFFAOYSA-N 0.000 claims 1
• JURBNJGMKDCGPC-UHFFFAOYSA-N [1-cyclopentyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1C1CCCC1 JURBNJGMKDCGPC-UHFFFAOYSA-N 0.000 claims 1
• CKOJBANBXKJJNP-UHFFFAOYSA-N [1-ethyl-3-(1-methylpiperidin-4-yl)indol-5-yl] 2,6-difluorobenzenesulfonate Chemical compound C12=CC(OS(=O)(=O)C=3C(=CC=CC=3F)F)=CC=C2N(CC)C=C1C1CCN(C)CC1 CKOJBANBXKJJNP-UHFFFAOYSA-N 0.000 claims 1
• GJZIZYFFTUJUTJ-UHFFFAOYSA-N [1-ethyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate Chemical compound C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(CC)C=C1C1CCN(C)CC1 GJZIZYFFTUJUTJ-UHFFFAOYSA-N 0.000 claims 1
• SFSUYMKRBGCOMD-UHFFFAOYSA-N [1-ethyl-7-methyl-3-(1-methylpiperidin-4-yl)indol-5-yl] 2,6-difluorobenzenesulfonate Chemical compound C12=CC(OS(=O)(=O)C=3C(=CC=CC=3F)F)=CC(C)=C2N(CC)C=C1C1CCN(C)CC1 SFSUYMKRBGCOMD-UHFFFAOYSA-N 0.000 claims 1
• PMYVKFSABBHMEE-UHFFFAOYSA-N [1-ethylsulfonyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate Chemical compound C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(S(=O)(=O)CC)C=C1C1CCN(C)CC1 PMYVKFSABBHMEE-UHFFFAOYSA-N 0.000 claims 1
• LYHNZWIPSZUYDT-UHFFFAOYSA-N [1-methyl-3-(1-methylpiperidin-4-yl)indol-5-yl] 2,6-difluorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CN(C)C1=CC=C2OS(=O)(=O)C1=C(F)C=CC=C1F LYHNZWIPSZUYDT-UHFFFAOYSA-N 0.000 claims 1
• YBAOMYVOYKBGGN-UHFFFAOYSA-N [1-methyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CN(C)C1=CC=C2OS(=O)(=O)C1=CC=CC=C1 YBAOMYVOYKBGGN-UHFFFAOYSA-N 0.000 claims 1
• OXCGLSVOGFFREO-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-(2-methylpropyl)indol-5-yl] benzenesulfonate Chemical compound C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(CC(C)C)C=C1C1CCN(C)CC1 OXCGLSVOGFFREO-UHFFFAOYSA-N 0.000 claims 1
• UAPHXSVMRKEIMU-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-(3-phenylpropyl)indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CCCC1=CC=CC=C1 UAPHXSVMRKEIMU-UHFFFAOYSA-N 0.000 claims 1
• ZWNRADRHWRNYME-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-(4-phenylbutyl)indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CCCCC1=CC=CC=C1 ZWNRADRHWRNYME-UHFFFAOYSA-N 0.000 claims 1
• IDGWQZSAMKQGHJ-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-(pyridin-2-ylmethyl)indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CC1=CC=CC=N1 IDGWQZSAMKQGHJ-UHFFFAOYSA-N 0.000 claims 1
• AZHRYUWDBDETMB-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-methylsulfonylindol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CN(S(C)(=O)=O)C1=CC=C2OS(=O)(=O)C1=CC=CC=C1 AZHRYUWDBDETMB-UHFFFAOYSA-N 0.000 claims 1
• AITBDGSOXAPXJG-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-naphthalen-1-ylsulfonylindol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CN(S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C1=CC=C2OS(=O)(=O)C1=CC=CC=C1 AITBDGSOXAPXJG-UHFFFAOYSA-N 0.000 claims 1
• ARZUHZLIMLZRTA-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-propan-2-ylindol-5-yl] 2,6-difluorobenzenesulfonate Chemical compound C12=CC(OS(=O)(=O)C=3C(=CC=CC=3F)F)=CC=C2N(C(C)C)C=C1C1CCN(C)CC1 ARZUHZLIMLZRTA-UHFFFAOYSA-N 0.000 claims 1
• OUTVFQCENMAWKE-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-propan-2-ylindol-5-yl] benzenesulfonate Chemical compound C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(C(C)C)C=C1C1CCN(C)CC1 OUTVFQCENMAWKE-UHFFFAOYSA-N 0.000 claims 1
• PDAJTEAXLXZDEB-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-propan-2-ylsulfonylindol-5-yl] benzenesulfonate Chemical compound C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(S(=O)(=O)C(C)C)C=C1C1CCN(C)CC1 PDAJTEAXLXZDEB-UHFFFAOYSA-N 0.000 claims 1
• JOBZMYQSDSPXHL-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-propylindol-5-yl] 2,6-difluorobenzenesulfonate Chemical compound C12=CC(OS(=O)(=O)C=3C(=CC=CC=3F)F)=CC=C2N(CCC)C=C1C1CCN(C)CC1 JOBZMYQSDSPXHL-UHFFFAOYSA-N 0.000 claims 1
• IPJJKOPLUSPNHF-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-propylsulfonylindol-5-yl] benzenesulfonate Chemical compound C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(S(=O)(=O)CCC)C=C1C1CCN(C)CC1 IPJJKOPLUSPNHF-UHFFFAOYSA-N 0.000 claims 1
• SGBLRMIQGXUDHH-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 2,3,4-trifluorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2OS(=O)(=O)C1=CC=C(F)C(F)=C1F SGBLRMIQGXUDHH-UHFFFAOYSA-N 0.000 claims 1
• BMDNGXPXZQYBBN-UHFFFAOYSA-N [4-(1-methylpiperidin-4-yl)-2,3-dihydro-1h-pyrrolo[1,2-a]indol-6-yl] 2,6-difluorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C(=CC=CC=2F)F)=CC=C11)=C2N1CCC2 BMDNGXPXZQYBBN-UHFFFAOYSA-N 0.000 claims 1
• BUVWOSLGQLYZLV-UHFFFAOYSA-N [7-methyl-3-(1-methylpiperidin-4-yl)-1-propylindol-5-yl] 2,6-difluorobenzenesulfonate Chemical compound C12=CC(OS(=O)(=O)C=3C(=CC=CC=3F)F)=CC(C)=C2N(CCC)C=C1C1CCN(C)CC1 BUVWOSLGQLYZLV-UHFFFAOYSA-N 0.000 claims 1
• KHYWCXKJGQMQLD-UHFFFAOYSA-N [7-methyl-3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 2,6-difluorobenzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=C(C)C=C2OS(=O)(=O)C1=C(F)C=CC=C1F KHYWCXKJGQMQLD-UHFFFAOYSA-N 0.000 claims 1
• FAOUPBYYGUBEBJ-UHFFFAOYSA-N [7-methyl-3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=C(C)C=C2OS(=O)(=O)C1=CC=CC=C1 FAOUPBYYGUBEBJ-UHFFFAOYSA-N 0.000 claims 1
• 125000005146 naphthylsulfonyl group Chemical group C1(=CC=CC2=CC=CC=C12)S(=O)(=O)* 0.000 claims 1
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 279
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 215
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 144
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 144
• 239000003921 oil Substances 0.000 description 83
• 235000019198 oils Nutrition 0.000 description 83
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 80
• 235000019439 ethyl acetate Nutrition 0.000 description 74
• 239000000243 solution Substances 0.000 description 73
• 239000007787 solid Substances 0.000 description 66
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 60
• 238000005160 1H NMR spectroscopy Methods 0.000 description 57
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
• 238000006243 chemical reaction Methods 0.000 description 54
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 48
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
• 239000000047 product Substances 0.000 description 47
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 46
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 45
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 43
• 208000035475 disorder Diseases 0.000 description 42
• 239000006185 dispersion Substances 0.000 description 42
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 41
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
• 229910001868 water Inorganic materials 0.000 description 40
• 239000002244 precipitate Substances 0.000 description 39
• 239000000203 mixture Substances 0.000 description 38
• 238000001914 filtration Methods 0.000 description 37
• 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 37
• 239000012458 free base Substances 0.000 description 35
• 239000011541 reaction mixture Substances 0.000 description 32
• NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 31
• 229910000105 potassium hydride Inorganic materials 0.000 description 31
• 241000700159 Rattus Species 0.000 description 29
• 150000002500 ions Chemical class 0.000 description 28
• 239000007921 spray Substances 0.000 description 28
• 239000000741 silica gel Substances 0.000 description 27
• 229910002027 silica gel Inorganic materials 0.000 description 27
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 26
• 238000011282 treatment Methods 0.000 description 26
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 25
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 25
• 229910000104 sodium hydride Inorganic materials 0.000 description 25
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 24
• 238000001035 drying Methods 0.000 description 24
• 238000001819 mass spectrum Methods 0.000 description 24
• 239000012312 sodium hydride Substances 0.000 description 24
• 239000002904 solvent Substances 0.000 description 24
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
• 238000003756 stirring Methods 0.000 description 20
• 238000004587 chromatography analysis Methods 0.000 description 19
• 239000006260 foam Substances 0.000 description 19
• 229910021529 ammonia Inorganic materials 0.000 description 17
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 16
• 241001465754 Metazoa Species 0.000 description 16
• 239000000843 powder Substances 0.000 description 16
• AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 16
• QXWAUQMMMIMLTO-UHFFFAOYSA-N 2,6-difluorobenzenesulfonyl chloride Chemical compound FC1=CC=CC(F)=C1S(Cl)(=O)=O QXWAUQMMMIMLTO-UHFFFAOYSA-N 0.000 description 15
• 238000012360 testing method Methods 0.000 description 15
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
• 239000012267 brine Substances 0.000 description 14
• 239000003795 chemical substances by application Substances 0.000 description 14
• 239000012043 crude product Substances 0.000 description 14
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
• 235000019270 ammonium chloride Nutrition 0.000 description 13
• 239000012044 organic layer Substances 0.000 description 13
• 235000006408 oxalic acid Nutrition 0.000 description 13
• 239000000725 suspension Substances 0.000 description 13
• WKNFADCGOAHBPG-UHFFFAOYSA-N 3-(1-methyl-4-piperidinyl)-1H-indol-5-ol Chemical compound C1CN(C)CCC1C1=CNC2=CC=C(O)C=C12 WKNFADCGOAHBPG-UHFFFAOYSA-N 0.000 description 12
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
• 230000003920 cognitive function Effects 0.000 description 12
• 230000000694 effects Effects 0.000 description 12
• 235000013305 food Nutrition 0.000 description 12
• CIRSPTXGPFAXRE-UHFFFAOYSA-N 3-(1,2,3,6-tetrahydropyridin-4-yl)-1h-indole Chemical compound C1NCCC(C=2C3=CC=CC=C3NC=2)=C1 CIRSPTXGPFAXRE-UHFFFAOYSA-N 0.000 description 11
• 208000019901 Anxiety disease Diseases 0.000 description 11
• 238000005481 NMR spectroscopy Methods 0.000 description 11
• 238000003818 flash chromatography Methods 0.000 description 11
• OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical class CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 10
• 101150041968 CDC13 gene Proteins 0.000 description 10
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• 239000000463 material Substances 0.000 description 10
• 229940044551 receptor antagonist Drugs 0.000 description 10
• 239000002464 receptor antagonist Substances 0.000 description 10
• XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 9
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 9
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
• 239000000908 ammonium hydroxide Substances 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 9
• 239000013078 crystal Substances 0.000 description 9
• 239000002480 mineral oil Substances 0.000 description 9
• 235000010446 mineral oil Nutrition 0.000 description 9
• 239000012071 phase Substances 0.000 description 9
• 102000005962 receptors Human genes 0.000 description 9
• 108020003175 receptors Proteins 0.000 description 9
• VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 8
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
• 208000019695 Migraine disease Diseases 0.000 description 8
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
• 230000006399 behavior Effects 0.000 description 8
• CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 8
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 8
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 8
• 239000012528 membrane Substances 0.000 description 8
• 206010027599 migraine Diseases 0.000 description 8
• 125000006239 protecting group Chemical group 0.000 description 8
• 239000000377 silicon dioxide Substances 0.000 description 8
• AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 8
• 238000001665 trituration Methods 0.000 description 8
• 230000036506 anxiety Effects 0.000 description 7
• 125000004432 carbon atom Chemical group C* 0.000 description 7
• 229960004170 clozapine Drugs 0.000 description 7
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 7
• 230000007278 cognition impairment Effects 0.000 description 7
• 239000012230 colorless oil Substances 0.000 description 7
• 238000001704 evaporation Methods 0.000 description 7
• 230000008020 evaporation Effects 0.000 description 7
• 238000000605 extraction Methods 0.000 description 7
• 239000012074 organic phase Substances 0.000 description 7
• 238000001556 precipitation Methods 0.000 description 7
• 239000002287 radioligand Substances 0.000 description 7
• 238000001953 recrystallisation Methods 0.000 description 7
• 239000003981 vehicle Substances 0.000 description 7
• HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 6
• KAIRZPVWWIMPFT-UHFFFAOYSA-N 3-piperidin-4-yl-1h-indole Chemical compound C1CNCCC1C1=CNC2=CC=CC=C12 KAIRZPVWWIMPFT-UHFFFAOYSA-N 0.000 description 6
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 6
• LOCQRDBFWSXQQI-UHFFFAOYSA-N 5-chloro-n-(4-methoxy-3-piperazin-1-ylphenyl)-3-methyl-1-benzothiophene-2-sulfonamide Chemical compound COC1=CC=C(NS(=O)(=O)C2=C(C3=CC(Cl)=CC=C3S2)C)C=C1N1CCNCC1 LOCQRDBFWSXQQI-UHFFFAOYSA-N 0.000 description 6
• 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 6
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
• 206010012289 Dementia Diseases 0.000 description 6
• 206010015866 Extravasation Diseases 0.000 description 6
• STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 6
• STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 6
• 125000000217 alkyl group Chemical group 0.000 description 6
• 238000010171 animal model Methods 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 238000010828 elution Methods 0.000 description 6
• 230000036251 extravasation Effects 0.000 description 6
• 239000011521 glass Substances 0.000 description 6
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 6
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
• 230000014759 maintenance of location Effects 0.000 description 6
• 230000015654 memory Effects 0.000 description 6
• 229910052757 nitrogen Inorganic materials 0.000 description 6
• 229910000069 nitrogen hydride Inorganic materials 0.000 description 6
• 229960005017 olanzapine Drugs 0.000 description 6
• KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 6
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
• 150000003254 radicals Chemical class 0.000 description 6
• STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 6
• 229960002646 scopolamine Drugs 0.000 description 6
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
• IVLXLWQMKWGZJO-UHFFFAOYSA-N 5-methoxy-7-methyl-3-(1-methylpiperidin-4-yl)-1h-indole Chemical compound C12=CC(OC)=CC(C)=C2NC=C1C1CCN(C)CC1 IVLXLWQMKWGZJO-UHFFFAOYSA-N 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 208000006011 Stroke Diseases 0.000 description 5
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 5
• 239000003693 atypical antipsychotic agent Substances 0.000 description 5
• 229940127236 atypical antipsychotics Drugs 0.000 description 5
• 239000002585 base Substances 0.000 description 5
• 239000002775 capsule Substances 0.000 description 5
• 239000003054 catalyst Substances 0.000 description 5
• 230000001713 cholinergic effect Effects 0.000 description 5
• 230000019771 cognition Effects 0.000 description 5
• 230000001149 cognitive effect Effects 0.000 description 5
• 235000008504 concentrate Nutrition 0.000 description 5
• 239000012141 concentrate Substances 0.000 description 5
• 230000006735 deficit Effects 0.000 description 5
• 239000003480 eluent Substances 0.000 description 5
• 239000012467 final product Substances 0.000 description 5
• 150000002431 hydrogen Chemical group 0.000 description 5
• 230000006872 improvement Effects 0.000 description 5
• 208000019906 panic disease Diseases 0.000 description 5
• 239000000546 pharmaceutical excipient Substances 0.000 description 5
• 208000020016 psychiatric disease Diseases 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 238000005070 sampling Methods 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
• 238000005406 washing Methods 0.000 description 5
• HHSDIWAVOYCKAW-UHFFFAOYSA-N 2,6-difluorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C(F)C=CC=C1F HHSDIWAVOYCKAW-UHFFFAOYSA-N 0.000 description 4
• CVPPUZPZPFOFPK-UHFFFAOYSA-N 2-phenylethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCC1=CC=CC=C1 CVPPUZPZPFOFPK-UHFFFAOYSA-N 0.000 description 4
• ARDASZJGLLMNAQ-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-1h-indol-5-ol Chemical compound C1N(C)CCC(C=2C3=CC(O)=CC=C3NC=2)=C1 ARDASZJGLLMNAQ-UHFFFAOYSA-N 0.000 description 4
• OCAMKBXBVVFIRI-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-5-phenylmethoxy-1h-indole Chemical compound C1N(C)CCC(C=2C3=CC(OCC=4C=CC=CC=4)=CC=C3NC=2)=C1 OCAMKBXBVVFIRI-UHFFFAOYSA-N 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 241001269524 Dura Species 0.000 description 4
• 208000011688 Generalised anxiety disease Diseases 0.000 description 4
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 4
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
• 239000002168 alkylating agent Substances 0.000 description 4
• 229940100198 alkylating agent Drugs 0.000 description 4
• 150000001412 amines Chemical class 0.000 description 4
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 239000000544 cholinesterase inhibitor Substances 0.000 description 4
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
• 239000000284 extract Substances 0.000 description 4
• 208000029364 generalized anxiety disease Diseases 0.000 description 4
• 230000000848 glutamatergic effect Effects 0.000 description 4
• 229910052736 halogen Inorganic materials 0.000 description 4
• 150000002367 halogens Chemical group 0.000 description 4
• 238000005984 hydrogenation reaction Methods 0.000 description 4
• 150000002475 indoles Chemical class 0.000 description 4
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
• 238000010992 reflux Methods 0.000 description 4
• 230000000698 schizophrenic effect Effects 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 239000012279 sodium borohydride Substances 0.000 description 4
• 229910000033 sodium borohydride Inorganic materials 0.000 description 4
• 229910052938 sodium sulfate Inorganic materials 0.000 description 4
• 235000011152 sodium sulphate Nutrition 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 229960001685 tacrine Drugs 0.000 description 4
• YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 4
• 238000012546 transfer Methods 0.000 description 4
• 238000002604 ultrasonography Methods 0.000 description 4
• DGRLPBVZZXUQNU-UHFFFAOYSA-N 1,7-dimethyl-3-(1-methylpiperidin-4-yl)indol-5-ol Chemical compound C1CN(C)CCC1C1=CN(C)C2=C(C)C=C(O)C=C12 DGRLPBVZZXUQNU-UHFFFAOYSA-N 0.000 description 3
• QLLURWREGSKAOH-UHFFFAOYSA-N 1-(2-amino-5-methoxy-3-methylphenyl)-2-chloroethanone Chemical compound COC1=CC(C)=C(N)C(C(=O)CCl)=C1 QLLURWREGSKAOH-UHFFFAOYSA-N 0.000 description 3
• XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 3
• KCWLEYXMVGFASS-OOJLDXBWSA-N 6-methyl-n-[(1s)-1-phenylethyl]-2,3,4,9-tetrahydro-1h-carbazol-1-amine Chemical compound C1([C@@H](NC2C3=C(C4=CC(C)=CC=C4N3)CCC2)C)=CC=CC=C1 KCWLEYXMVGFASS-OOJLDXBWSA-N 0.000 description 3
• OKIIXXYTLLZHGZ-UHFFFAOYSA-N 7-bromo-1h-indol-5-ol Chemical compound OC1=CC(Br)=C2NC=CC2=C1 OKIIXXYTLLZHGZ-UHFFFAOYSA-N 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 201000004810 Vascular dementia Diseases 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• 239000012131 assay buffer Substances 0.000 description 3
• 230000027455 binding Effects 0.000 description 3
• 125000001309 chloro group Chemical group Cl* 0.000 description 3
• 239000000812 cholinergic antagonist Substances 0.000 description 3
• 230000003750 conditioning effect Effects 0.000 description 3
• 239000002024 ethyl acetate extract Substances 0.000 description 3
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
• 229910052737 gold Inorganic materials 0.000 description 3
• 239000010931 gold Substances 0.000 description 3
• 229960003878 haloperidol Drugs 0.000 description 3
• 210000001320 hippocampus Anatomy 0.000 description 3
• 239000005457 ice water Substances 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 3
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
• 239000010410 layer Substances 0.000 description 3
• 230000013016 learning Effects 0.000 description 3
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
• 208000027061 mild cognitive impairment Diseases 0.000 description 3
• 150000007530 organic bases Chemical class 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 210000002442 prefrontal cortex Anatomy 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 238000004007 reversed phase HPLC Methods 0.000 description 3
• 229960001534 risperidone Drugs 0.000 description 3
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 239000003751 serotonin 6 antagonist Substances 0.000 description 3
• 230000035939 shock Effects 0.000 description 3
• 238000012453 sprague-dawley rat model Methods 0.000 description 3
• 230000024188 startle response Effects 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 238000006277 sulfonation reaction Methods 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• KKBXMEPZZFWIIA-UHFFFAOYSA-N tert-butyl-dimethyl-[[3-(1-methylpiperidin-4-yl)-1h-indol-5-yl]oxy]silane Chemical compound C1CN(C)CCC1C1=CNC2=CC=C(O[Si](C)(C)C(C)(C)C)C=C12 KKBXMEPZZFWIIA-UHFFFAOYSA-N 0.000 description 3
• 210000000427 trigeminal ganglion Anatomy 0.000 description 3
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
• MKGFBPHSWVXXQQ-UHFFFAOYSA-N (3-bromo-4-nitrophenoxy)-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OC1=CC=C([N+]([O-])=O)C(Br)=C1 MKGFBPHSWVXXQQ-UHFFFAOYSA-N 0.000 description 2
• RMCJYFDGGOXIGR-UHFFFAOYSA-N (7-bromo-1h-indol-5-yl)oxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OC1=CC(Br)=C2NC=CC2=C1 RMCJYFDGGOXIGR-UHFFFAOYSA-N 0.000 description 2
• NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 2
• RSVWBMLBRFHPOS-UHFFFAOYSA-N 1-benzyl-3-(1-methylpiperidin-4-yl)indol-5-ol Chemical compound C1CN(C)CCC1C(C1=CC(O)=CC=C11)=CN1CC1=CC=CC=C1 RSVWBMLBRFHPOS-UHFFFAOYSA-N 0.000 description 2
• WGDFVIWPQQELHW-UHFFFAOYSA-N 1-benzyl-7-methyl-3-(1-methylpiperidin-4-yl)indol-5-ol Chemical compound C1CN(C)CCC1C(C1=CC(O)=CC(C)=C11)=CN1CC1=CC=CC=C1 WGDFVIWPQQELHW-UHFFFAOYSA-N 0.000 description 2
• APZRMJJULAMQAA-UHFFFAOYSA-N 1-bromo-4-fluoro-5-methoxy-2-nitrobenzene Chemical compound COC1=CC(Br)=C([N+]([O-])=O)C=C1F APZRMJJULAMQAA-UHFFFAOYSA-N 0.000 description 2
• CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 2
• DSJITLRFLSAQBQ-UHFFFAOYSA-N 1-methyl-3-(1-methylpiperidin-4-yl)indol-5-ol Chemical compound C1CN(C)CCC1C1=CN(C)C2=CC=C(O)C=C12 DSJITLRFLSAQBQ-UHFFFAOYSA-N 0.000 description 2
• SVYWEZZHXINQHC-UHFFFAOYSA-N 2-bromo-5-fluoro-4-methoxyaniline Chemical compound COC1=CC(Br)=C(N)C=C1F SVYWEZZHXINQHC-UHFFFAOYSA-N 0.000 description 2
• FQVDCOMEPMOYKM-UHFFFAOYSA-N 2-methyl-3-(1-methylpiperidin-4-yl)-1h-indol-5-ol Chemical compound C1CN(C)CCC1C1=C(C)NC2=CC=C(O)C=C12 FQVDCOMEPMOYKM-UHFFFAOYSA-N 0.000 description 2
• QIMRPGAQCKHRKB-UHFFFAOYSA-N 2-methylpropyl 4-methylbenzenesulfonate Chemical compound CC(C)COS(=O)(=O)C1=CC=C(C)C=C1 QIMRPGAQCKHRKB-UHFFFAOYSA-N 0.000 description 2
• SEHWKDYHCVIOFF-UHFFFAOYSA-N 3-(1-methyl-2h-pyridin-4-yl)-1h-indol-5-ol Chemical compound C1=CN(C)CC=C1C1=CNC2=CC=C(O)C=C12 SEHWKDYHCVIOFF-UHFFFAOYSA-N 0.000 description 2
• 229940124801 5-HT6 antagonist Drugs 0.000 description 2
• 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
• 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
• GUJOCYGHAMPXTP-UHFFFAOYSA-N 5-methoxy-1,7-dimethyl-3-(1-methylpiperidin-4-yl)indole Chemical compound C12=CC(OC)=CC(C)=C2N(C)C=C1C1CCN(C)CC1 GUJOCYGHAMPXTP-UHFFFAOYSA-N 0.000 description 2
• YGPVRHHGKCQSIL-UHFFFAOYSA-N 5-methoxy-7-methyl-1h-indole Chemical compound COC1=CC(C)=C2NC=CC2=C1 YGPVRHHGKCQSIL-UHFFFAOYSA-N 0.000 description 2
• POLLWUBKYBKASK-UHFFFAOYSA-N 5-methoxy-7-methyl-3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-1h-indole Chemical compound C12=CC(OC)=CC(C)=C2NC=C1C1=CCN(C)CC1 POLLWUBKYBKASK-UHFFFAOYSA-N 0.000 description 2
• JUMLPCNEQSZMGS-UHFFFAOYSA-N 5-methoxy-7-methyl-3-(1-methylpiperidin-4-yl)-1-propylindole Chemical compound C12=CC(OC)=CC(C)=C2N(CCC)C=C1C1CCN(C)CC1 JUMLPCNEQSZMGS-UHFFFAOYSA-N 0.000 description 2
• DANYGEQACAPBOK-UHFFFAOYSA-N 6-fluoro-5-methoxy-1h-indole Chemical compound C1=C(F)C(OC)=CC2=C1NC=C2 DANYGEQACAPBOK-UHFFFAOYSA-N 0.000 description 2
• YOPHRXPGVSWBMM-UHFFFAOYSA-N 6-fluoro-5-methoxy-3-(1-methylpiperidin-4-yl)-1h-indole Chemical compound C=1NC=2C=C(F)C(OC)=CC=2C=1C1CCN(C)CC1 YOPHRXPGVSWBMM-UHFFFAOYSA-N 0.000 description 2
• RAIGWIFXIOCQTH-UHFFFAOYSA-N 6-methoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-2,3-dihydro-1h-pyrrolo[1,2-a]indole Chemical compound C12=CC(OC)=CC=C2N2CCCC2=C1C1=CCN(C)CC1 RAIGWIFXIOCQTH-UHFFFAOYSA-N 0.000 description 2
• QZOLLSISPJGZED-UHFFFAOYSA-N 7-methyl-3-(1-methylpiperidin-4-yl)-1-propylindol-5-ol Chemical compound C12=CC(O)=CC(C)=C2N(CCC)C=C1C1CCN(C)CC1 QZOLLSISPJGZED-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 208000008811 Agoraphobia Diseases 0.000 description 2
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
• 229930003347 Atropine Natural products 0.000 description 2
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
• 208000020925 Bipolar disease Diseases 0.000 description 2
• 201000006474 Brain Ischemia Diseases 0.000 description 2
• 206010008120 Cerebral ischaemia Diseases 0.000 description 2
• RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 2
• 229940122041 Cholinesterase inhibitor Drugs 0.000 description 2
• 208000027691 Conduct disease Diseases 0.000 description 2
• 206010010774 Constipation Diseases 0.000 description 2
• 206010010904 Convulsion Diseases 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 206010019196 Head injury Diseases 0.000 description 2
• 206010019233 Headaches Diseases 0.000 description 2
• 208000010496 Heart Arrest Diseases 0.000 description 2
• 208000023105 Huntington disease Diseases 0.000 description 2
• RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
• 206010022998 Irritability Diseases 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 208000020358 Learning disease Diseases 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 206010026749 Mania Diseases 0.000 description 2
• 208000019022 Mood disease Diseases 0.000 description 2
• 238000012347 Morris Water Maze Methods 0.000 description 2
• 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
• 206010028813 Nausea Diseases 0.000 description 2
• 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 2
• 208000012902 Nervous system disease Diseases 0.000 description 2
• 208000025966 Neurological disease Diseases 0.000 description 2
• 208000018737 Parkinson disease Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 206010034960 Photophobia Diseases 0.000 description 2
• 229920002873 Polyethylenimine Polymers 0.000 description 2
• 241001282135 Poromitra oscitans Species 0.000 description 2
• 208000028017 Psychotic disease Diseases 0.000 description 2
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
• 206010047700 Vomiting Diseases 0.000 description 2
• 206010048232 Yawning Diseases 0.000 description 2
• DVFPVVHLYSOXBO-UHFFFAOYSA-N [1-(benzenesulfonyl)-3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)indol-5-yl] benzenesulfonate;hydrochloride Chemical compound Cl.C1N(C)CCC(C=2C3=CC(OS(=O)(=O)C=4C=CC=CC=4)=CC=C3N(C=2)S(=O)(=O)C=2C=CC=CC=2)=C1 DVFPVVHLYSOXBO-UHFFFAOYSA-N 0.000 description 2
• SSRZWXWNOMKIEK-UHFFFAOYSA-N [7-bromo-3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-1h-indol-5-yl] benzenesulfonate Chemical compound C1N(C)CCC(C=2C3=CC(OS(=O)(=O)C=4C=CC=CC=4)=CC(Br)=C3NC=2)=C1 SSRZWXWNOMKIEK-UHFFFAOYSA-N 0.000 description 2
• GANYMSDHMBJFIL-UHFFFAOYSA-N acetonitrile;ethoxyethane Chemical compound CC#N.CCOCC GANYMSDHMBJFIL-UHFFFAOYSA-N 0.000 description 2
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
• 239000012346 acetyl chloride Substances 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 230000006978 adaptation Effects 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• 125000003545 alkoxy group Chemical group 0.000 description 2
• 230000029936 alkylation Effects 0.000 description 2
• 238000005804 alkylation reaction Methods 0.000 description 2
• VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
• 238000000540 analysis of variance Methods 0.000 description 2
• 150000008064 anhydrides Chemical class 0.000 description 2
• 239000000074 antisense oligonucleotide Substances 0.000 description 2
• 238000012230 antisense oligonucleotides Methods 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
• 229960000396 atropine Drugs 0.000 description 2
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
• 229940049706 benzodiazepine Drugs 0.000 description 2
• 150000001557 benzodiazepines Chemical class 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 125000001246 bromo group Chemical group Br* 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 206010008118 cerebral infarction Diseases 0.000 description 2
• 229960003920 cocaine Drugs 0.000 description 2
• 238000009833 condensation Methods 0.000 description 2
• 230000005494 condensation Effects 0.000 description 2
• 230000036461 convulsion Effects 0.000 description 2
• 125000006165 cyclic alkyl group Chemical group 0.000 description 2
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 201000010099 disease Diseases 0.000 description 2
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 206010015037 epilepsy Diseases 0.000 description 2
• FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 231100000869 headache Toxicity 0.000 description 2
• 239000003326 hypnotic agent Substances 0.000 description 2
• 230000000147 hypnotic effect Effects 0.000 description 2
• 230000002218 hypoglycaemic effect Effects 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 239000002198 insoluble material Substances 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 201000010901 lateral sclerosis Diseases 0.000 description 2
• 201000003723 learning disability Diseases 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 230000007787 long-term memory Effects 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 235000019341 magnesium sulphate Nutrition 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 208000005264 motor neuron disease Diseases 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 201000003631 narcolepsy Diseases 0.000 description 2
• 230000008693 nausea Effects 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 230000000926 neurological effect Effects 0.000 description 2
• 230000003955 neuronal function Effects 0.000 description 2
• 230000003961 neuronal insult Effects 0.000 description 2
• 229960002715 nicotine Drugs 0.000 description 2
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
• 229940127240 opiate Drugs 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 150000003891 oxalate salts Chemical class 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• 208000033300 perinatal asphyxia Diseases 0.000 description 2
• 230000000737 periodic effect Effects 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 229940068917 polyethylene glycols Drugs 0.000 description 2
• SDQCGKJCBWXRMK-UHFFFAOYSA-N propan-2-yl 4-methylbenzenesulfonate Chemical compound CC(C)OS(=O)(=O)C1=CC=C(C)C=C1 SDQCGKJCBWXRMK-UHFFFAOYSA-N 0.000 description 2
• 238000010791 quenching Methods 0.000 description 2
• 230000000171 quenching effect Effects 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 239000000932 sedative agent Substances 0.000 description 2
• 229940125723 sedative agent Drugs 0.000 description 2
• 229940076279 serotonin Drugs 0.000 description 2
• 230000006403 short-term memory Effects 0.000 description 2
• 210000003625 skull Anatomy 0.000 description 2
• 208000019116 sleep disease Diseases 0.000 description 2
• QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
• 238000000527 sonication Methods 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 238000013222 sprague-dawley male rat Methods 0.000 description 2
• 239000008223 sterile water Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 239000011975 tartaric acid Substances 0.000 description 2
• 235000002906 tartaric acid Nutrition 0.000 description 2
• 230000002123 temporal effect Effects 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• 235000019505 tobacco product Nutrition 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 238000012549 training Methods 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• 230000008673 vomiting Effects 0.000 description 2
• 239000003643 water by type Substances 0.000 description 2
• 230000003936 working memory Effects 0.000 description 2
• PHZOVXDZZMVGIX-UHFFFAOYSA-N (7-bromo-1h-indol-5-yl) benzenesulfonate Chemical compound C=1C=2C=CNC=2C(Br)=CC=1OS(=O)(=O)C1=CC=CC=C1 PHZOVXDZZMVGIX-UHFFFAOYSA-N 0.000 description 1
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
• AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 description 1
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
• UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• IBLMYGXJKQIGSN-UHFFFAOYSA-N 1-(bromomethyl)-2,4-difluorobenzene Chemical compound FC1=CC=C(CBr)C(F)=C1 IBLMYGXJKQIGSN-UHFFFAOYSA-N 0.000 description 1
• FFWQLZFIMNTUCZ-UHFFFAOYSA-N 1-(bromomethyl)-2-fluorobenzene Chemical compound FC1=CC=CC=C1CBr FFWQLZFIMNTUCZ-UHFFFAOYSA-N 0.000 description 1
• SCBZBMXPJYMXRC-UHFFFAOYSA-N 1-(bromomethyl)-3-fluorobenzene Chemical compound FC1=CC=CC(CBr)=C1 SCBZBMXPJYMXRC-UHFFFAOYSA-N 0.000 description 1
• GXONHAWXKCSSNY-UHFFFAOYSA-N 1-benzyl-5-methoxy-7-methyl-3-(1-methylpiperidin-4-yl)indole Chemical compound C1=C(C2CCN(C)CC2)C2=CC(OC)=CC(C)=C2N1CC1=CC=CC=C1 GXONHAWXKCSSNY-UHFFFAOYSA-N 0.000 description 1
• UWPUJVOSEQMMQE-UHFFFAOYSA-N 1-bromo-4,5-difluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=C(F)C=C1Br UWPUJVOSEQMMQE-UHFFFAOYSA-N 0.000 description 1
• KSQDIPJHNSKKDC-UHFFFAOYSA-N 1-ethyl-5-methoxy-7-methyl-3-(1-methylpiperidin-4-yl)indole Chemical compound C12=CC(OC)=CC(C)=C2N(CC)C=C1C1CCN(C)CC1 KSQDIPJHNSKKDC-UHFFFAOYSA-N 0.000 description 1
• OAEPJLWDHWBKMS-UHFFFAOYSA-N 1-methyl-3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-5-phenylmethoxyindole Chemical compound C1N(C)CCC(C=2C3=CC(OCC=4C=CC=CC=4)=CC=C3N(C)C=2)=C1 OAEPJLWDHWBKMS-UHFFFAOYSA-N 0.000 description 1
• SZNPONDDJIPWRZ-UHFFFAOYSA-N 1-methyl-3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-5-phenylmethoxyindole;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(C)CCC(C=2C3=CC(OCC=4C=CC=CC=4)=CC=C3N(C)C=2)=C1 SZNPONDDJIPWRZ-UHFFFAOYSA-N 0.000 description 1
• KUWOSKFQJGYTMD-UHFFFAOYSA-N 1-methyl-3-(1-methylpiperidin-4-yl)indol-5-ol oxalic acid Chemical compound OC(=O)C(O)=O.CN1CCC(CC1)c1cn(C)c2ccc(O)cc12 KUWOSKFQJGYTMD-UHFFFAOYSA-N 0.000 description 1
• GGYVTHJIUNGKFZ-UHFFFAOYSA-N 1-methylpiperidin-2-one Chemical compound CN1CCCCC1=O GGYVTHJIUNGKFZ-UHFFFAOYSA-N 0.000 description 1
• RTMMSCJWQYWMNK-UHFFFAOYSA-N 2,2,2-trifluoroethyl trifluoromethanesulfonate Chemical compound FC(F)(F)COS(=O)(=O)C(F)(F)F RTMMSCJWQYWMNK-UHFFFAOYSA-N 0.000 description 1
• XFTDZYFHXRZLEF-UHFFFAOYSA-N 2,3,4-trifluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C(F)=C1F XFTDZYFHXRZLEF-UHFFFAOYSA-N 0.000 description 1
• HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
• FJSAJUXIHJIAMD-UHFFFAOYSA-N 2,4-difluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C(F)=C1 FJSAJUXIHJIAMD-UHFFFAOYSA-N 0.000 description 1
• WGGKQIKICKLWGN-UHFFFAOYSA-N 2,6-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=CC(Cl)=C1S(Cl)(=O)=O WGGKQIKICKLWGN-UHFFFAOYSA-N 0.000 description 1
• ZEYRDXUWJDGTLD-UHFFFAOYSA-N 2-(2-ethyl-5-methoxy-1h-indol-3-yl)-n,n-dimethylethanamine Chemical compound C1=C(OC)C=C2C(CCN(C)C)=C(CC)NC2=C1 ZEYRDXUWJDGTLD-UHFFFAOYSA-N 0.000 description 1
• NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
• JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 1
• ZSZKAQCISWFDCQ-UHFFFAOYSA-N 2-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=CC=C1S(Cl)(=O)=O ZSZKAQCISWFDCQ-UHFFFAOYSA-N 0.000 description 1
• IVHKZCSZELZKSJ-UHFFFAOYSA-N 2-hydroxyethyl sulfonate Chemical compound OCCOS(=O)=O IVHKZCSZELZKSJ-UHFFFAOYSA-N 0.000 description 1
• VOCGFCFUCRKECD-UHFFFAOYSA-N 2-methyl-3-(1-methylpiperidin-4-yl)-1h-indol-5-ol;hydrochloride Chemical compound Cl.C1CN(C)CCC1C1=C(C)NC2=CC=C(O)C=C12 VOCGFCFUCRKECD-UHFFFAOYSA-N 0.000 description 1
• SOOFMUVYYKOZHX-UHFFFAOYSA-N 3-(1-methylpiperidin-4-yl)-1-(1-phenylethyl)indol-5-ol Chemical compound C1=C(C2CCN(C)CC2)C2=CC(O)=CC=C2N1C(C)C1=CC=CC=C1 SOOFMUVYYKOZHX-UHFFFAOYSA-N 0.000 description 1
• GUDTUYPAPRJPBL-UHFFFAOYSA-N 3-(1-methylpiperidin-4-yl)-5-phenylmethoxy-1h-indole Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2OCC1=CC=CC=C1 GUDTUYPAPRJPBL-UHFFFAOYSA-N 0.000 description 1
• SZYVPWPBRABKAB-UHFFFAOYSA-N 3-bromo-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C(Br)=C1 SZYVPWPBRABKAB-UHFFFAOYSA-N 0.000 description 1
• XMZQWZJMTBCUFT-UHFFFAOYSA-N 3-bromopropylbenzene Chemical compound BrCCCC1=CC=CC=C1 XMZQWZJMTBCUFT-UHFFFAOYSA-N 0.000 description 1
• YMQPKONILWWJQG-UHFFFAOYSA-N 4-bromo-1,2-difluorobenzene Chemical compound FC1=CC=C(Br)C=C1F YMQPKONILWWJQG-UHFFFAOYSA-N 0.000 description 1
• PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
• ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 1
• FLLZCZIHURYEQP-UHFFFAOYSA-N 4-chlorobutylbenzene Chemical compound ClCCCCC1=CC=CC=C1 FLLZCZIHURYEQP-UHFFFAOYSA-N 0.000 description 1
• BFXHJFKKRGVUMU-UHFFFAOYSA-N 4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1 BFXHJFKKRGVUMU-UHFFFAOYSA-N 0.000 description 1
• POXFXTSTVWDWIR-UHFFFAOYSA-N 4-iodobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(I)C=C1 POXFXTSTVWDWIR-UHFFFAOYSA-N 0.000 description 1
• DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 1
• JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
• OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
• YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
• GEHRSERUQRFUFW-UHFFFAOYSA-N 5-ethylhex-2-ynedioic acid Chemical compound CCC(C(O)=O)CC#CC(O)=O GEHRSERUQRFUFW-UHFFFAOYSA-N 0.000 description 1
• 101710150235 5-hydroxytryptamine receptor 6 Proteins 0.000 description 1
• ATQMNHIHTXFMGY-UHFFFAOYSA-N 5-methoxy-2-methyl-3-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)-1H-indole 5-methoxy-2-methyl-3-(1-methylpiperidin-4-yl)-1H-indole hydrochloride Chemical compound COC=1C=C2C(=C(NC2=CC1)C)C=1CCN(CC1)C.Cl.COC=1C=C2C(=C(NC2=CC1)C)C1CCN(CC1)C ATQMNHIHTXFMGY-UHFFFAOYSA-N 0.000 description 1
• JCQLPDZCNSVBMS-UHFFFAOYSA-N 5-phenylmethoxy-1h-indole Chemical compound C=1C=C2NC=CC2=CC=1OCC1=CC=CC=C1 JCQLPDZCNSVBMS-UHFFFAOYSA-N 0.000 description 1
• DZKFVPDUHDGOQN-UHFFFAOYSA-N 6-fluoro-5-methoxy-3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-1h-indole Chemical compound C=1NC=2C=C(F)C(OC)=CC=2C=1C1=CCN(C)CC1 DZKFVPDUHDGOQN-UHFFFAOYSA-N 0.000 description 1
• FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
• ACCXJZLEGLVYNB-UHFFFAOYSA-N 6-methoxy-2,3-dihydro-1h-pyrrolo[1,2-a]indole Chemical compound COC1=CC=C2N(CCC3)C3=CC2=C1 ACCXJZLEGLVYNB-UHFFFAOYSA-N 0.000 description 1
• OCSKUOXVLATEOY-UHFFFAOYSA-N 8-methoxy-1-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinoline Chemical compound C1=2C3=CC(OC)=CC=2CCCN1C=C3C1=CCN(C)CC1 OCSKUOXVLATEOY-UHFFFAOYSA-N 0.000 description 1
• JEZBJWRSEFQAMN-UHFFFAOYSA-N 8-methoxy-5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinoline Chemical compound C1CCN2C=CC3=CC(OC)=CC1=C32 JEZBJWRSEFQAMN-UHFFFAOYSA-N 0.000 description 1
• MGWJEFCEQNNQCL-UHFFFAOYSA-N 8-methoxy-5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinoline-1,2-dione Chemical compound C1CCC2=CC(OC)=CC3=C2N1C(=O)C3=O MGWJEFCEQNNQCL-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
• 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
• 206010002859 Anxiety disorder due to a general medical condition Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• YNFWWPRJTXXUIH-UHFFFAOYSA-N COC=1C=C2C=CC=NC2=CC1.COC=1C=C2CCCNC2=CC1 Chemical compound COC=1C=C2C=CC=NC2=CC1.COC=1C=C2CCCNC2=CC1 YNFWWPRJTXXUIH-UHFFFAOYSA-N 0.000 description 1
• FAMLILPAUFSVIW-UHFFFAOYSA-N COC=1C=C2CCCN3C2=C(C1)C(C3=O)=O.COC=3C=C1CCCN2C1=C(C3)C=C2 Chemical compound COC=1C=C2CCCN3C2=C(C1)C(C3=O)=O.COC=3C=C1CCCN2C1=C(C3)C=C2 FAMLILPAUFSVIW-UHFFFAOYSA-N 0.000 description 1
• 0 C[C@@](CCN(*)CC1)C1c1c(*)[n](*)c(c(*)c2*)c1cc2OS(c1ccccc1)(=O)=O Chemical compound C[C@@](CCN(*)CC1)C1c1c(*)[n](*)c(c(*)c2*)c1cc2OS(c1ccccc1)(=O)=O 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• FHBFGTJAHQOFAC-UHFFFAOYSA-N Cl.C1=C(C2CCN(C)CC2)C2=CC(OS(=O)(=O)C=3C(=CC=CC=3F)F)=CC=C2N1C(C)C1=CC=CC=C1 Chemical compound Cl.C1=C(C2CCN(C)CC2)C2=CC(OS(=O)(=O)C=3C(=CC=CC=3F)F)=CC=C2N1C(C)C1=CC=CC=C1 FHBFGTJAHQOFAC-UHFFFAOYSA-N 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 238000001061 Dunnett's test Methods 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 238000006783 Fischer indole synthesis reaction Methods 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• 108090000862 Ion Channels Proteins 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 239000004166 Lanolin Substances 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
• 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
• QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• JQTMFTOBGHNVSV-UHFFFAOYSA-N OC(=O)C(O)=O.C1=C(C2CCN(C)CC2)C2=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N1C(C)C1=CC=CC=C1 Chemical compound OC(=O)C(O)=O.C1=C(C2CCN(C)CC2)C2=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N1C(C)C1=CC=CC=C1 JQTMFTOBGHNVSV-UHFFFAOYSA-N 0.000 description 1
• GFRROZIJVHUSKZ-FXGMSQOLSA-N OS I Natural products C[C@@H]1O[C@@H](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](OC[C@@H](O)[C@@H](O)[C@@H](O)CO)[C@@H]2NC(=O)C)[C@H](O)[C@H](O)[C@H]1O GFRROZIJVHUSKZ-FXGMSQOLSA-N 0.000 description 1
• 235000019502 Orange oil Nutrition 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 239000004264 Petrolatum Substances 0.000 description 1
• 206010034912 Phobia Diseases 0.000 description 1
• PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 101000964045 Rattus norvegicus 5-hydroxytryptamine receptor 6 Proteins 0.000 description 1
• 241000220010 Rhode Species 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• 206010041250 Social phobia Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
• ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
• MJUGJFZVWOJTGI-UHFFFAOYSA-N [1-(2,6-difluorophenyl)sulfonyl-3-(1-methylpiperidin-4-yl)indol-5-yl] 2,6-difluorobenzenesulfonate;hydrochloride Chemical compound Cl.C1CN(C)CCC1C(C1=C2)=CN(S(=O)(=O)C=3C(=CC=CC=3F)F)C1=CC=C2OS(=O)(=O)C1=C(F)C=CC=C1F MJUGJFZVWOJTGI-UHFFFAOYSA-N 0.000 description 1
• OOKIHCOLOQPERZ-UHFFFAOYSA-N [1-(cyclohexylmethyl)-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate;hydrochloride Chemical compound Cl.C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CC1CCCCC1 OOKIHCOLOQPERZ-UHFFFAOYSA-N 0.000 description 1
• IQPVDWUPCZVWPB-UHFFFAOYSA-N [1-[(2,4-difluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CC1=CC=C(F)C=C1F IQPVDWUPCZVWPB-UHFFFAOYSA-N 0.000 description 1
• JSKCIVXABYBUNC-UHFFFAOYSA-N [1-[(2-fluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate;hydrochloride Chemical compound Cl.C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CC1=CC=CC=C1F JSKCIVXABYBUNC-UHFFFAOYSA-N 0.000 description 1
• QWBBAUPZULIMEM-UHFFFAOYSA-N [1-[(3-fluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate;hydrochloride Chemical compound Cl.C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CC1=CC=CC(F)=C1 QWBBAUPZULIMEM-UHFFFAOYSA-N 0.000 description 1
• IMEOHLFYXXKFSD-UHFFFAOYSA-N [1-[(4-fluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)indol-5-yl] 2,6-difluorobenzenesulfonate;hydrochloride Chemical compound Cl.C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C(=CC=CC=2F)F)=CC=C11)=CN1CC1=CC=C(F)C=C1 IMEOHLFYXXKFSD-UHFFFAOYSA-N 0.000 description 1
• MLZMTFUIWLLPDZ-UHFFFAOYSA-N [1-[(4-fluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate;hydrochloride Chemical compound Cl.C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CC1=CC=C(F)C=C1 MLZMTFUIWLLPDZ-UHFFFAOYSA-N 0.000 description 1
• VNLYNCZNUYXERW-UHFFFAOYSA-N [1-[(4-fluorophenyl)methyl]-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CC1=CC=C(F)C=C1 VNLYNCZNUYXERW-UHFFFAOYSA-N 0.000 description 1
• ZLKPDCPWQPSBAZ-UHFFFAOYSA-N [1-benzyl-3-(1-methylpiperidin-4-yl)indol-5-yl] 2,6-difluorobenzenesulfonate;hydrochloride Chemical compound Cl.C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C(=CC=CC=2F)F)=CC=C11)=CN1CC1=CC=CC=C1 ZLKPDCPWQPSBAZ-UHFFFAOYSA-N 0.000 description 1
• DCRILSKQCJYPEA-UHFFFAOYSA-N [1-benzyl-3-(1-methylpiperidin-4-yl)indol-5-yl] 2,6-difluorobenzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C(=CC=CC=2F)F)=CC=C11)=CN1CC1=CC=CC=C1 DCRILSKQCJYPEA-UHFFFAOYSA-N 0.000 description 1
• NBQQLWGQJUKQSS-UHFFFAOYSA-N [1-benzyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate;hydrochloride Chemical compound Cl.C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CC1=CC=CC=C1 NBQQLWGQJUKQSS-UHFFFAOYSA-N 0.000 description 1
• LOAUVXRXDGAMNH-UHFFFAOYSA-N [1-benzylsulfonyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C1CN(C)CCC1C(C1=C2)=CN(S(=O)(=O)CC=3C=CC=CC=3)C1=CC=C2OS(=O)(=O)C1=CC=CC=C1 LOAUVXRXDGAMNH-UHFFFAOYSA-N 0.000 description 1
• JGXXIPUASSKEGY-UHFFFAOYSA-N [1-butyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate;hydrochloride Chemical compound Cl.C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(CCCC)C=C1C1CCN(C)CC1 JGXXIPUASSKEGY-UHFFFAOYSA-N 0.000 description 1
• XLECNUFCXYNFLO-UHFFFAOYSA-N [1-butyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(CCCC)C=C1C1CCN(C)CC1 XLECNUFCXYNFLO-UHFFFAOYSA-N 0.000 description 1
• MAECURMBVWQSQY-UHFFFAOYSA-N [1-cyclohexyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1C1CCCCC1 MAECURMBVWQSQY-UHFFFAOYSA-N 0.000 description 1
• YXMOSNUJIGMJKW-UHFFFAOYSA-N [1-cyclopentyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1C1CCCC1 YXMOSNUJIGMJKW-UHFFFAOYSA-N 0.000 description 1
• UCTJYBXEFGVIHN-UHFFFAOYSA-N [1-ethyl-3-(1-methylpiperidin-4-yl)indol-5-yl] 2,6-difluorobenzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C12=CC(OS(=O)(=O)C=3C(=CC=CC=3F)F)=CC=C2N(CC)C=C1C1CCN(C)CC1 UCTJYBXEFGVIHN-UHFFFAOYSA-N 0.000 description 1
• WQGUJWZISDTQCZ-UHFFFAOYSA-N [1-ethyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(CC)C=C1C1CCN(C)CC1 WQGUJWZISDTQCZ-UHFFFAOYSA-N 0.000 description 1
• AWZASALBTJXKLA-UHFFFAOYSA-N [1-ethyl-7-methyl-3-(1-methylpiperidin-4-yl)indol-5-yl] 2,6-difluorobenzenesulfonate;hydrochloride Chemical compound Cl.C12=CC(OS(=O)(=O)C=3C(=CC=CC=3F)F)=CC(C)=C2N(CC)C=C1C1CCN(C)CC1 AWZASALBTJXKLA-UHFFFAOYSA-N 0.000 description 1
• SVURJHOKJAULSR-UHFFFAOYSA-N [1-ethylsulfonyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(S(=O)(=O)CC)C=C1C1CCN(C)CC1 SVURJHOKJAULSR-UHFFFAOYSA-N 0.000 description 1
• XQGFYENETWVJEU-UHFFFAOYSA-N [1-methyl-3-(1-methylpiperidin-4-yl)indol-5-yl] 2,6-difluorobenzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C1CN(C)CCC1C(C1=C2)=CN(C)C1=CC=C2OS(=O)(=O)C1=C(F)C=CC=C1F XQGFYENETWVJEU-UHFFFAOYSA-N 0.000 description 1
• ROWBQCJKFJVPJG-UHFFFAOYSA-N [1-methyl-3-(1-methylpiperidin-4-yl)indol-5-yl] benzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C1CN(C)CCC1C(C1=C2)=CN(C)C1=CC=C2OS(=O)(=O)C1=CC=CC=C1 ROWBQCJKFJVPJG-UHFFFAOYSA-N 0.000 description 1
• BFPOCAMOEFDNCF-UHFFFAOYSA-N [3-(1-methyl-2h-pyridin-4-yl)-1h-indol-5-yl] benzenesulfonate Chemical compound C1=CN(C)CC=C1C(C1=C2)=CNC1=CC=C2OS(=O)(=O)C1=CC=CC=C1 BFPOCAMOEFDNCF-UHFFFAOYSA-N 0.000 description 1
• CYEDDKVUNOCDGH-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-(2-methylpropyl)indol-5-yl] benzenesulfonate;hydrochloride Chemical compound Cl.C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(CC(C)C)C=C1C1CCN(C)CC1 CYEDDKVUNOCDGH-UHFFFAOYSA-N 0.000 description 1
• WISWXVWVWSFXLU-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-(3-phenylpropyl)indol-5-yl] benzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CCCC1=CC=CC=C1 WISWXVWVWSFXLU-UHFFFAOYSA-N 0.000 description 1
• XFRLCEXFRUMJFJ-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-(4-phenylbutyl)indol-5-yl] benzenesulfonate;hydrochloride Chemical compound Cl.C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CCCCC1=CC=CC=C1 XFRLCEXFRUMJFJ-UHFFFAOYSA-N 0.000 description 1
• MZGQBHADVCBACS-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-(pyridin-2-ylmethyl)indol-5-yl] benzenesulfonate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1CN(C)CCC1C(C1=CC(OS(=O)(=O)C=2C=CC=CC=2)=CC=C11)=CN1CC1=CC=CC=N1 MZGQBHADVCBACS-UHFFFAOYSA-N 0.000 description 1
• XIQFYAVFCQFVMO-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-methylsulfonylindol-5-yl] benzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C1CN(C)CCC1C(C1=C2)=CN(S(C)(=O)=O)C1=CC=C2OS(=O)(=O)C1=CC=CC=C1 XIQFYAVFCQFVMO-UHFFFAOYSA-N 0.000 description 1
• PRCWNROWRYKQEP-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-naphthalen-1-ylsulfonylindol-5-yl] benzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C1CN(C)CCC1C(C1=C2)=CN(S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C1=CC=C2OS(=O)(=O)C1=CC=CC=C1 PRCWNROWRYKQEP-UHFFFAOYSA-N 0.000 description 1
• AHUXJOMNBISPJV-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-propan-2-ylindol-5-yl] 2,6-difluorobenzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C12=CC(OS(=O)(=O)C=3C(=CC=CC=3F)F)=CC=C2N(C(C)C)C=C1C1CCN(C)CC1 AHUXJOMNBISPJV-UHFFFAOYSA-N 0.000 description 1
• FJEQHBLTDNEDNB-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-propan-2-ylindol-5-yl] benzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(C(C)C)C=C1C1CCN(C)CC1 FJEQHBLTDNEDNB-UHFFFAOYSA-N 0.000 description 1
• XGNKYJKVRIGQPX-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-propan-2-ylsulfonylindol-5-yl] benzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(S(=O)(=O)C(C)C)C=C1C1CCN(C)CC1 XGNKYJKVRIGQPX-UHFFFAOYSA-N 0.000 description 1
• RRTSABFNJZPVEU-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-propylindol-5-yl] 2,6-difluorobenzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C12=CC(OS(=O)(=O)C=3C(=CC=CC=3F)F)=CC=C2N(CCC)C=C1C1CCN(C)CC1 RRTSABFNJZPVEU-UHFFFAOYSA-N 0.000 description 1
• UUQFYRMLNYKWAC-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-propylindol-5-yl] benzenesulfonate;hydrochloride Chemical compound Cl.C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(CCC)C=C1C1CCN(C)CC1 UUQFYRMLNYKWAC-UHFFFAOYSA-N 0.000 description 1
• RYGMFKCLTLFUOF-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1-propylsulfonylindol-5-yl] benzenesulfonate;oxalic acid Chemical compound OC(=O)C(O)=O.C12=CC(OS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(S(=O)(=O)CCC)C=C1C1CCN(C)CC1 RYGMFKCLTLFUOF-UHFFFAOYSA-N 0.000 description 1
• ZPRHNRHTMZEULH-UHFFFAOYSA-N [3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] 4-(methanesulfonamido)benzenesulfonate;hydrochloride Chemical compound Cl.C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2OS(=O)(=O)C1=CC=C(NS(C)(=O)=O)C=C1 ZPRHNRHTMZEULH-UHFFFAOYSA-N 0.000 description 1
• WOWZVNZQZSBQHF-UHFFFAOYSA-N [7-bromo-3-(1-methyl-2h-pyridin-4-yl)-1h-indol-5-yl] benzenesulfonate Chemical compound C1=CN(C)CC=C1C(C1=C2)=CNC1=C(Br)C=C2OS(=O)(=O)C1=CC=CC=C1 WOWZVNZQZSBQHF-UHFFFAOYSA-N 0.000 description 1
• QQEYNNGVGRFKAU-UHFFFAOYSA-N [7-bromo-3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=C(Br)C=C2OS(=O)(=O)C1=CC=CC=C1 QQEYNNGVGRFKAU-UHFFFAOYSA-N 0.000 description 1
• QQDZCRDZEXVQRQ-UHFFFAOYSA-N [7-ethenyl-3-(1-methylpiperidin-4-yl)-1h-indol-5-yl] benzenesulfonate Chemical compound C1CN(C)CCC1C(C1=C2)=CNC1=C(C=C)C=C2OS(=O)(=O)C1=CC=CC=C1 QQDZCRDZEXVQRQ-UHFFFAOYSA-N 0.000 description 1
• OTIJGURNROWSEM-UHFFFAOYSA-N [7-methyl-3-(1-methylpiperidin-4-yl)-1-propylindol-5-yl] 2,6-difluorobenzenesulfonate;hydrochloride Chemical compound Cl.C12=CC(OS(=O)(=O)C=3C(=CC=CC=3F)F)=CC(C)=C2N(CCC)C=C1C1CCN(C)CC1 OTIJGURNROWSEM-UHFFFAOYSA-N 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
• 229960004373 acetylcholine Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 208000026345 acute stress disease Diseases 0.000 description 1
• 102000030621 adenylate cyclase Human genes 0.000 description 1
• 108060000200 adenylate cyclase Proteins 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000007000 age related cognitive decline Effects 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
• 125000000304 alkynyl group Chemical group 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
• 229960000836 amitriptyline Drugs 0.000 description 1
• 230000003109 amnesic effect Effects 0.000 description 1
• 229940025084 amphetamine Drugs 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000561 anti-psychotic effect Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 159000000032 aromatic acids Chemical class 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 238000000376 autoradiography Methods 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• 229940092738 beeswax Drugs 0.000 description 1
• 238000009227 behaviour therapy Methods 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000002051 biphasic effect Effects 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000001045 blue dye Substances 0.000 description 1
• UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
• UUWSLBWDFJMSFP-UHFFFAOYSA-N bromomethylcyclohexane Chemical compound BrCC1CCCCC1 UUWSLBWDFJMSFP-UHFFFAOYSA-N 0.000 description 1
• KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 210000004027 cell Anatomy 0.000 description 1
• 210000003710 cerebral cortex Anatomy 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 235000015218 chewing gum Nutrition 0.000 description 1
• JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
• KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
• 230000006949 cholinergic function Effects 0.000 description 1
• 210000002932 cholinergic neuron Anatomy 0.000 description 1
• 238000011097 chromatography purification Methods 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229940114081 cinnamate Drugs 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 230000003931 cognitive performance Effects 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 229940124301 concurrent medication Drugs 0.000 description 1
• 238000007596 consolidation process Methods 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 239000013058 crude material Substances 0.000 description 1
• OHHPZPDQZMUTCA-UHFFFAOYSA-N cyclohexyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1CCCCC1 OHHPZPDQZMUTCA-UHFFFAOYSA-N 0.000 description 1
• GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 150000001991 dicarboxylic acids Chemical class 0.000 description 1
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• YNLAOSYQHBDIKW-UHFFFAOYSA-M diethylaluminium chloride Chemical compound CC[Al](Cl)CC YNLAOSYQHBDIKW-UHFFFAOYSA-M 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 229960003530 donepezil Drugs 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 229960001484 edetic acid Drugs 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
• VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
• RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
• FNZLVSZSBPEFPL-UHFFFAOYSA-N ethyl n-(2-bromo-5-fluoro-4-methoxyphenyl)carbamate Chemical compound CCOC(=O)NC1=CC(F)=C(OC)C=C1Br FNZLVSZSBPEFPL-UHFFFAOYSA-N 0.000 description 1
• DENJGVOANBFJAW-UHFFFAOYSA-N ethyl n-[5-fluoro-4-methoxy-2-(2-trimethylsilylethynyl)phenyl]carbamate Chemical compound CCOC(=O)NC1=CC(F)=C(OC)C=C1C#C[Si](C)(C)C DENJGVOANBFJAW-UHFFFAOYSA-N 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 239000010685 fatty oil Substances 0.000 description 1
• 230000035611 feeding Effects 0.000 description 1
• 210000003191 femoral vein Anatomy 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 230000002431 foraging effect Effects 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 238000003304 gavage Methods 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000000971 hippocampal effect Effects 0.000 description 1
• 230000008801 hippocampal function Effects 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 210000004283 incisor Anatomy 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 238000000185 intracerebroventricular administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 230000003447 ipsilateral effect Effects 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
• TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229940039717 lanolin Drugs 0.000 description 1
• 235000019388 lanolin Nutrition 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 239000011344 liquid material Substances 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 1
• IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
• 229940095102 methyl benzoate Drugs 0.000 description 1
• STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
• 229940012189 methyl orange Drugs 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 229960001383 methylscopolamine Drugs 0.000 description 1
• 238000001690 micro-dialysis Methods 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940042472 mineral oil Drugs 0.000 description 1
• 239000012046 mixed solvent Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
• PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 210000001577 neostriatum Anatomy 0.000 description 1
• 230000010004 neural pathway Effects 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 230000008284 neuronal mechanism Effects 0.000 description 1
• 230000007979 neuropsychological functioning Effects 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 210000001009 nucleus accumben Anatomy 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 210000001010 olfactory tubercle Anatomy 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 239000010502 orange oil Substances 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 229940066842 petrolatum Drugs 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
• 229940049953 phenylacetate Drugs 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• 229950009215 phenylbutanoic acid Drugs 0.000 description 1
• OAHKWDDSKCRNFE-UHFFFAOYSA-N phenylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1=CC=CC=C1 OAHKWDDSKCRNFE-UHFFFAOYSA-N 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 229960001697 physostigmine Drugs 0.000 description 1
• PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
• 229910003446 platinum oxide Inorganic materials 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 208000028173 post-traumatic stress disease Diseases 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
• BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• KPBSJEBFALFJTO-UHFFFAOYSA-N propane-1-sulfonyl chloride Chemical compound CCCS(Cl)(=O)=O KPBSJEBFALFJTO-UHFFFAOYSA-N 0.000 description 1
• DRINJBFRTLBHNF-UHFFFAOYSA-N propane-2-sulfonyl chloride Chemical compound CC(C)S(Cl)(=O)=O DRINJBFRTLBHNF-UHFFFAOYSA-N 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
• 230000020978 protein processing Effects 0.000 description 1
• 239000004089 psychotropic agent Substances 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 229960004431 quetiapine Drugs 0.000 description 1
• URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 210000004761 scalp Anatomy 0.000 description 1
• 229940116351 sebacate Drugs 0.000 description 1
• CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
• 239000012056 semi-solid material Substances 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 238000010898 silica gel chromatography Methods 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
• 239000008259 solid foam Substances 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 201000001716 specific phobia Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 229940086735 succinate Drugs 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 235000011149 sulphuric acid Nutrition 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000000153 supplemental effect Effects 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
• 238000012353 t test Methods 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 1
• FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
• 230000031836 visual learning Effects 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 238000010792 warming Methods 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 229940071104 xylenesulfonate Drugs 0.000 description 1